Skip to main content

CRDF

Stock
Health Care
Biotechnology

Performance overview

CRDF Price
Price Chart

Forward-looking statistics

Beta
1.27
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").

Company info

SectorHealth Care
IndustryBiotechnology
Employees37
Market cap$131.1M

Fundamentals

Enterprise value
Revenue
Revenue per employee
Profit margin
Debt to equity

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)
Dividend per share
Revenue per share
Avg trading volume (30 day)
Avg trading volume (10 day)
Put-call ratio

Macro factor sensitivity

Growth-3.7
Credit+11.2
Liquidity+2.6
Inflation-7.8
Commodities-2.8
Interest Rates-1.8

Valuation

Dividend yield0.00%
PEG Ratio
Price to sales
P/E Ratio-3.04
Enterprise Value to Revenue
Price to book

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day
Ex. dividend day

News

Cardiff Oncology (CRDF) Upgraded to Buy: Here's What You Should Know

Cardiff Oncology (CRDF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research (May 14, 2025)
Cardiff Oncology Slumps On New Data From Lead Program In Metastatic Colorectal Cancer

Cardiff Oncology Inc (NASDAQ: CRDF) posted new data from Phase 1b/2 trial of onvansertib combined with standard-of-care (SOC) FOLFIRI/bevacizumab for second-line KRAS-mutated metastatic colorectal cancer (mCRC). The data will be shared at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

Benzinga (January 19, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free